Mary Wilson
Well-known member
November 9, 2022
doi:10.1001/jamanetworkopen.2022.41144
Rohan Khazanchi, MD, MPH[SUP]1,2,3[/SUP]; Andrew Strumpf, MPH[SUP]4[/SUP]; Utibe R. Essien, MD, MPH[SUP]5,6[/SUP]; et al
Introduction
Nirmatrelvir-ritonavir and molnupiravir are oral antivirals that reduce risk of hospitalization for people with mild to moderate COVID-19.[SUP]1[/SUP] Timely access to treatment is a priority because these medications are indicated within 5 days of symptom onset. In March 2022, the Biden Administration announced the Test to Treat initiative to designate one-stop locations where people can receive a COVID-19 test, speak with a clinician, obtain an antiviral prescription, and fill the prescription for free.[SUP]2[/SUP] However, concerns remain that the Test to Treat program may not be accessible for minoritized and high-risk populations.[SUP]3[/SUP][SUP]-5[/SUP] To explore geographic disparities in antiviral access, we quantified the accessibility of Test to Treat sites for subpopulations by race, ethnicity, age, and rurality.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2798225
doi:10.1001/jamanetworkopen.2022.41144
Rohan Khazanchi, MD, MPH[SUP]1,2,3[/SUP]; Andrew Strumpf, MPH[SUP]4[/SUP]; Utibe R. Essien, MD, MPH[SUP]5,6[/SUP]; et al
Introduction
Nirmatrelvir-ritonavir and molnupiravir are oral antivirals that reduce risk of hospitalization for people with mild to moderate COVID-19.[SUP]1[/SUP] Timely access to treatment is a priority because these medications are indicated within 5 days of symptom onset. In March 2022, the Biden Administration announced the Test to Treat initiative to designate one-stop locations where people can receive a COVID-19 test, speak with a clinician, obtain an antiviral prescription, and fill the prescription for free.[SUP]2[/SUP] However, concerns remain that the Test to Treat program may not be accessible for minoritized and high-risk populations.[SUP]3[/SUP][SUP]-5[/SUP] To explore geographic disparities in antiviral access, we quantified the accessibility of Test to Treat sites for subpopulations by race, ethnicity, age, and rurality.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2798225